Meyer Lab

Meyer

The Meyer lab is investigating the interaction of heart rate and calcium cycling in heart failure with preserved ejection fraction (HFpEF). A main goal is the development of chronotherapy to improve symptoms and outcomes in HFpEF. In a bench-to-bedside approach we study disease models, human heart tissue samples and conduct clinical studies.

Dr. Meyer holds the Engdahl Family Foundation Chair in Heart Failure Research.

Markus Meyer faculty profile

Current Lab Projects
  • Heart rate effects on cardiac hemodynamics and the myocardium
  • Novel approaches and pharmacologic targets in HFpEF
  • Mechanisms and dosing of chronotherapy
  • Biosensor to monitor sarcoplasmic reticulum dependent relaxation
Selected Publications

Full list of publications at Experts@Minnesota.

  1. Meyer M. Diastolic Tone-Friend and Foe of Cardiac Performance. Circ Heart Fail. 2023 Dec;16(12):e011307. doi: 10.1161/CIRCHEARTFAILURE.123.011307. Epub 2023 Dec 19. PMID: 38113299.
  2. Wahlberg KJ, Infeld M, Plante TB, Novelli AE, Habel N, Burkhoff D, Barrett T, Lustgarten D, Meyer M. Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial. J Am Heart Assoc. 2023 Dec 29:e9139. doi: 10.1161/JAHA.123.032873. Epub ahead of print. PMID: 38156545.
  3. Meyer M, Infeld M, Habel N, Lustgarten DL. Personalized Accelerated Physiologic Pacing. Eur Heart J Suppl. 2023 Nov 9;25(Suppl G):G33-G43. doi: 10.1093/eurheartjsupp/suad117. PMID: 37970518; PMCID: PMC10637836.
  4. BoYe, Bradshaw AD, Abrahante JE, Dragon JA, Häußler TN, Bell SP, Hirashima F, LeWinter M, Zile MR, Meyer M. Left Ventricular Gene Expression in Heart Failure with Preserved Ejection Fraction - Pro-fibrotic and Pro-inflammatory Pathways and Genes. Circ Heart Fail. 2023 Aug;16(8):e010395. doi: 10.1161/CIRCHEARTFAILURE.123.010395. Epub 2023 Jul 27. PMID: 37582166.
  5. Weissler-Snir A, Rakowski H, Meyer M. Beta-blockers in Non-obstructive Hypertrophic Cardiomyopathy: Time to Ease the Heart Rate Restriction? Eur Heart J. 2023 Oct 1;44(37):3655-3657. doi: 10.1093/eurheartj/ehad518. PMID: 37650505.
  6. Habel N, du Fay de Lavallaz J, Infeld M, Koehler JL, Ziegler PD, Lustgarten DL, Meyer M. Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation. Int J Cardiol Cardiovasc Risk Prev. 2023 Feb 25;17:200182. doi: 10.1016/j.ijcrp.2023.200182. PMID: 36911071; PMCID: PMC9996284.
  7. Infeld M, Wahlberg K, Cicero J, Plante TB, Meagher S, Novelli A, Habel N, Krishnan AM, Silverman DN, LeWinter MM, Lustgarten DL, Meyer M. Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial. JAMA Cardiol. 2023 Feb 1. doi: 10.1001/jamacardio.2022.5320. Epub ahead of print. PMID: 36723919.
  8. Meyer M, Lustgarten D. Beta-blockers in atrial fibrillation - trying to make sense of unsettling results. Europace. 2023 doi: 10.1093/europace/euad010. PMID: 36748952; PMCID: PMC9935022
  9. Silverman DN, du Fay de Lavallaz J, Plante TB, Infeld MM, Goyal P, Juraschek SP, Dougherty GB, Callas PW, Meyer M. Beta-blocker Use in Hypertension and Heart Failure Outcomes - A Secondary Analysis of the Systolic Blood Pressure Intervention Trial [SPRINT]). Am J Cardiol. 2022. https://doi.org/10.1016/j.amjcard.2021.10.049
  10. Meyer M, LeWinter MM, Zile MR. A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone. Circulation. 2021 Oct 19;144(16):1269-1271. doi: 10.1161/CIRCULATIONAHA.121.056412. Epub 2021 Oct 18.
Contact Info

Email:
[email protected]

Phone:
(612) 625-9538

Fax:
(612) 301-8298

Office Address:
4-165 Cancer & Cardiovascular Research Building